Octant in the News

December 12, 2023
Octant announces the appointment of Chris Sinz, Matthew Albert, Rebecca Velez Frey, and Wen-Chen Yeh to key leadership positions
June 13, 2022
Octant wins "Technology and Tools" Award at Mutational Scanning Symposium 2022
See Octant poster presentation on Deep Mutational Scanning
Octant Bio
April 22, 2022
Octant: leveraging cell barcoding for small molecule design
BioCentury
April 21, 2022
BMS joins Octant’s $80M financing and signs on as a drug discovery partner
MedCity News
April 21, 2022
Octant Bio accepts $80m
Global Corporate Venturing
April 21, 2022
Octant Scores $80M in Series B Funds, Partnership with BMS
BioSpace
April 21, 2022
Synthetic biology biotech nets three-hit combo in new financing, Bristol Myers deal and first CSO
Endpoints News
April 21, 2022
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership
Fierce Biotech
January 18, 2022
SwabSeq: Scalable, Sensitive and Fast COVID-19 Testing
UCLA Newsroom
January 5, 2022
Octant continues pursuit of drug discovery
California NanoSystems Institute
December 10, 2020
Ginkgo Bioworks, Octant to Establish Bay Area Coronavirus Test Processing Facility
GenomeWeb
December 10, 2020
How Open Source Bio-tech Scored a Deal for an East Bay Startup
San Francisco Business Times
October 9, 2020
New UCLA coronavirus test has about 95% reliability rate: Octant CEO
Fox Business
June 29, 2020
Pharma’s Dirty Secret, And The Synthetic Biology Startup Offering A New Approach
Forbes
May 20, 2020
Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs
BioCentury
May 20, 2020
Navigating new world of synthetic biology, East Bay startup lands $30M, maps future of drug discovery
San Francisco Business Times
May 20, 2020
Andreessen Horowitz backs a new molecule builder from UCLA equipped with the latest in convergence tech. And he’s aiming big
Endpoints News
May 20, 2020
With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs
Xconomy
May 20, 2020
Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery
TechCrunch